Medication info

Pulmicom Suspension for Nebulization (Budesonide)

Prescription medicationSuspensionExternal use
Ingredient · strength
Budesonide Micronized›0.5mg
Manufacturer / importer
Geonil Pharmaceutical Co., Ltd.
Appearance
A uniform white-gray suspension for mucosal nebulization filled in a single-use plastic bottle.
Packaging
(2mL x 5 bottles) x 6/case
Approval status
Active

MFDS item code 200100450 · Notified 2001.09.24 · Insurance code 646801361

Summary

Main use
Treatment of bronchial asthma and acute laryngotracheobronchitis (croup) in infants and children
Who uses it
Adults · Children
Adult use
This drug should be administered using a suitable nebulizer. The dose delivered to the patient is approximately 40~60% of the labeled dose and varies depending on the nebulizer used. The nebulization time and dose depend on the flow rate, nebulizer chamber, and fill volume; an appropriate fill volume for most nebulizers is 2~4 milliliters. Bronchial asthma — At initiation of inhalation therapy, during treatment of severe asthma, or when reducing or discontinuing oral corticosteroids: Adults; administer 1~2 milligrams (2 vials~4 vials) twice daily Bronchial asthma — Maintenance dose: This varies by individual and should be administered at the lowest possible dose. The recommended maintenance dose is as follows. Adults; administer 0.5~1 milligram (1 vial~2 vials) twice daily For patients seeking to enhance the therapeutic effect, increasing the dose of this drug is generally preferable to combination therapy with oral corticosteroids, as it carries a lower risk of systemic adverse effects. In particular, when there is no mucus secretion in the airways, it is preferable to administer this drug before administering oral corticosteroids.
Child use
Bronchial asthma — At initiation of inhalation therapy, during treatment of severe asthma, or when reducing or discontinuing oral corticosteroids: Children; administer 0.5~1 milligram (1 vial~2 vials) twice daily Bronchial asthma — Maintenance dose: Children; administer 0.25~0.5 milligram (½ vial~1 vial) twice daily Acute laryngotracheobronchitis — In infants and young children, administer 2 mg once daily.

Ingredients

Manufacturer
Geonil Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of bronchial asthma and acute laryngotracheobronchitis (croup) in infants and children

  • Bronchial asthma
  • acute laryngotracheobronchitis
View approved original text

This medication is used for bronchial asthma, particularly when symptoms are not adequately controlled by steroid treatment alone. It is also effective for the treatment of acute laryngotracheobronchitis, commonly known as croup, in infants and children. It helps alleviate inflammation in the bronchi and promotes smoother breathing to improve symptoms. This drug is used to relieve symptoms for patients suffering from respiratory diseases and assist in recovery.

How to use

Adult use

This drug should be administered using a suitable nebulizer. The dose delivered to the patient is approximately 40~60% of the labeled dose and varies depending on the nebulizer used. The nebulization time and dose depend on the flow rate, nebulizer chamber, and fill volume; an appropriate fill volume for most nebulizers is 2~4 milliliters. Bronchial asthma — At initiation of inhalation therapy, during treatment of severe asthma, or when reducing or discontinuing oral corticosteroids: Adults; administer 1~2 milligrams (2 vials~4 vials) twice daily Bronchial asthma — Maintenance dose: This varies by individual and should be administered at the lowest possible dose. The recommended maintenance dose is as follows. Adults; administer 0.5~1 milligram (1 vial~2 vials) twice daily For patients seeking to enhance the therapeutic effect, increasing the dose of this drug is generally preferable to combination therapy with oral corticosteroids, as it carries a lower risk of systemic adverse effects. In particular, when there is no mucus secretion in the airways, it is preferable to administer this drug before administering oral corticosteroids.

Child use

Bronchial asthma — At initiation of inhalation therapy, during treatment of severe asthma, or when reducing or discontinuing oral corticosteroids: Children; administer 0.5~1 milligram (1 vial~2 vials) twice daily Bronchial asthma — Maintenance dose: Children; administer 0.25~0.5 milligram (½ vial~1 vial) twice daily Acute laryngotracheobronchitis — In infants and young children, administer 2 mg once daily.

Precautions

This medication contains the ingredient budesonide, which is used to alleviate asthma or bronchial inflammation. Individuals allergic to any components in this medication or to budesonide should not use it. Patients with pulmonary tuberculosis or fungal and viral infections should exercise special caution when using this drug, and patients dependent on steroids should gradually adjust the dosage under a doctor's guidance. Side effects such as sore throat, oral inflammation, dry mouth, cough, hoarseness, and oral candidiasis may occur; therefore, rinsing the mouth well after use is essential. Rarely, symptoms like headache, taste abnormalities, skin rash, bronchospasm, anxiety, or depression can occur, so consult a doctor if any abnormal symptoms arise. This medication is not suitable for rapid relief of asthma symptoms and should generally be used alongside other treatments rather than alone. When switching from oral steroids to this medication, it is crucial to follow the doctor's directions, as adrenal function recovery may take time. Appropriate antibiotic treatment may be necessary in cases of infection, and care should be taken not to worsen infection symptoms. Always consult a doctor or pharmacist before stopping or changing the dosage of this medication. While no significant risks to the fetus have been reported during pregnancy, it is important to consult a doctor before use. It is relatively safe during breastfeeding, but the benefits and risks should be weighed. If used in children, the minimal effective dose should be used, and their growth should be monitored regularly to prevent impact on growth. While overdose often does not exhibit special symptoms, prolonged excessive use may lead to issues such as adrenal suppression, so caution is advised. After inhalation, wash the mouth and face with water to prevent candidiasis infection, and do not use the medication if it is not adequately mixed. This drug is for inhalation use only and should not be ingested or injected.

Side effects

  • sore throat
  • stomatitis and glossitis
  • dry mouth
  • cough
  • oral candidiasis
  • hoarseness
  • laryngitis
  • headache
  • cervicodynia
  • dysgeusia
Show 17 more
  • thirst
  • diarrhea
  • nausea
  • weight gain
  • fatigue
  • urticaria
  • rash
  • dermatitis
  • angioedema
  • bronchospasm
  • anxiety
  • restlessness
  • depression
  • bronchial stricture
  • skin laceration
  • facial skin irritation
  • blurred vision

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light, so it should be stored in a sealed container within the provided foil pouch. It is recommended to maintain storage temperatures between 1 and 30 degrees Celsius to preserve the drug's effectiveness.

Appearance and packaging

Appearance

A uniform white-gray suspension for mucosal nebulization filled in a single-use plastic bottle.

Package unit

(2mL x 5 bottles) x 6/case

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.